Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

neoantigen-based renal cell carcinoma-poly-ICLC vaccine

A peptide-based renal cell carcinoma (RCC) vaccine consisting of neoantigens and peptides derived from immunogenic epitopes identified through DNA and RNA sequencing of a patient's tumor cells, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based RCC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:NeoVax RCC vaccine
NeoVax renal cell carcinoma vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search